Righini Matteo, Capelli Irene, Busutti Marco, Raimondi Concettina, Comai Giorgia, Donati Gabriele, Cappuccilli Maria Laura, Ravaioli Matteo, Chieco Pasquale, La Manna Gaetano
Nephrology, Dialysis and Transplantation Unit, IRCCS-Azienda Ospedaliero Universitaria di Bologna, Alma Mater Studiorum, University of Bologna, 40100 Bologna, Italy.
Nephrology and Dialysis Unit, Santa Maria delle Croci Hospital, 48100 Ravenna, Italy.
J Clin Med. 2022 Feb 17;11(4):1054. doi: 10.3390/jcm11041054.
Renal transplantation represents the therapeutic gold standard in patients with end stage renal disease (ESRD). Still the role of pre-transplant dialysis in affecting time to transplantation has yet to be determined. We wanted to verify whether the type of renal replacement therapy (hemodialysis vs. peritoneal dialysis) affects time to transplantation and to identify clinical features related to the longer time to transplantation.
We performed a retrospective single-center observational study on patients who had received a transplant in the Bologna Transplant Unit from 1991 to 2019, described through the analysis of digital transplant list documents for sex, age, body mass index (BMI), blood group, comorbidities, underlying disease, serology, type of dialysis, time to transplantation, Panel Reactive Antibodies (PRA) max, number of preformed anti Human Leukocyte Antigens (HLA) antibodies. A -value < 0.05 was considered statistically significant.
In the 1619 patients analyzed, we observed a significant difference in time to transplant, PRA max and Preformed Antibodies Number between patients who received Hemodialysis (HD) and Peritoneal dialysis (PD). Then we performed a multiple regression analysis with all the considered factors in order to identify features that support these differences. The clinical variables that independently and directly correlate with longer time to transplantation are PRA max ( < 0.0001), Antibodies number ( < 0.0001) and HD ( < 0.0001); though AB blood group ( < 0.0001), age ( < 0.003) and PD ( < 0.0001) inversely correlate with time to transplantation.
In our work, PD population received renal transplants in a shorter period of time compared to HD and turned out to be less immunized. Considering immunization, the type of dialysis impacts both on PRA max and on anti HLA antibodies.
肾移植是终末期肾病(ESRD)患者的治疗金标准。然而,移植前透析对移植时间的影响尚未确定。我们想验证肾脏替代治疗的类型(血液透析与腹膜透析)是否会影响移植时间,并确定与较长移植时间相关的临床特征。
我们对1991年至2019年在博洛尼亚移植中心接受移植的患者进行了一项回顾性单中心观察性研究,通过分析数字移植列表文件来描述患者的性别、年龄、体重指数(BMI)、血型、合并症、基础疾病、血清学、透析类型、移植时间、群体反应性抗体(PRA)最大值、预先形成的抗人类白细胞抗原(HLA)抗体数量。P值<0.05被认为具有统计学意义。
在分析的1619例患者中,我们观察到接受血液透析(HD)和腹膜透析(PD)的患者在移植时间、PRA最大值和预先形成的抗体数量方面存在显著差异。然后,我们对所有考虑的因素进行了多元回归分析,以确定支持这些差异的特征。与较长移植时间独立且直接相关的临床变量是PRA最大值(P<0.0001)、抗体数量(P<0.0001)和HD(P<0.0001);而AB血型(P<0.0001)、年龄(P<0.003)和PD(P<0.0001)与移植时间呈负相关。
在我们的研究中,与HD相比,PD人群接受肾移植的时间更短,且免疫程度更低。考虑到免疫情况,透析类型对PRA最大值和抗HLA抗体均有影响。